Company News: StrikeForce Communications and Makovsky + Co.

Share this article:
Alcon has awarded two accounts to StrikeForce Communications, including global strategic and creative responsibilities for I-Caps, a line of ocular nutrition products aimed at delaying the progress of age related macular degeneration, and for OTC dry eye therapy Systane. The New York-based shop also recently won an assignment for Orexigen Theraeutics' obesity drug, which is under FDA review.

Makovsky + Company has been retained by Neoprobe Corp., for its strategic communications and investor relations program as the Dublin, Ohio-based firm, which makes surgical oncology products, prepares for the commercialization of Lymphoseek and the launch of a RIGS clinical development program.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.